

Letter of Intent signed with Kaivogen Oy to produce Lumito's complete reagent kits

Lumito AB and the Finnish company Kaivogen Oy have signed a Letter of Intent to produce Lumito's immunohistochemistry reagent kit, which is part of the company's complete product offering in digital tissue analysis. The ambition is to launch the product in research laboratories in the latter part of 2022.

Lumito's product consists of a scanner and UCNP (Up Converting Nano Particles)-based labelling fluids (reagents) for various disease markers. In April this year, Lumito signed a collaboration agreement for O-series production of the company's scanner with Optronics Partner pr AB. The product has the potential to improve tissue diagnostics by meeting the increasing need for specific tissue analysis through higher analytical quality and shorter analysis times. The technology is based on an IHC reagent kit with Lumito's UCNPs acting as tumor reporters.

- *We are proud that Lumito has chosen us as their manufacturing partner. Lumito's unique platform combined with our proven know-how of nanoparticle-based upconversion technology has created this exciting opportunity for both companies, comments Leena Kokko, CEO Kaivogen, a Uniogen group company.*
- *At Uniogen we are continually evaluating new ways to bring value to our industrial partners through our processes and research based innovations. We are excited about the collaboration with Lumito in the field of tissue diagnostics, says Ilari Antila, CEO of Uniogen.*
- *The letter of intent signed with Kaivogen is an important step to secure production of our complete reagent kit consisting of UCNPs and our staining fluid, for the upcoming product launch in research labs, says Mattias Lundin, Lumito's CEO.*

[Read more about Lumitos technology.](#)

[Link to press release "Lumito signs cooperation agreement with Optronic för O-series production".](#)

For further information, please contact:

Lumito's CEO, Mattias Lundin
E-mail: ml@lumito.se
phone: +46 76-868 45 09

Also, visit our [website](#).

Kaivogen, a Uniogen company, is a specialist in immunoassays and antibody tests, and a trusted partner for custom IVD assays. Uniogen is a global pioneer in clinical diagnostics, point-of-care testing and instruments for life sciences. The company provides solutions for clinical laboratories, in-vitro diagnostic companies, research organizations and pharmaceutical service companies. Upcon is ideal for variety of applications including quantitative bioaffinity assays, microscopy and imaging. Upcon™ is a registered trademark of Kaivogen. Additional information about Uniogen, based in Turku, Finland, is available at www.uniogen.com

Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. www.lumito.se.

The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 (8) 5030 1550 and email, ca@mangold.se.